A detailed history of Ensign Peak Advisors, Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 42,668 shares of HALO stock, worth $2.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,668
Previous 42,668 -0.0%
Holding current value
$2.03 Million
Previous $2.23 Million 9.27%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$33.68 - $41.95 $9.97 Million - $12.4 Million
-295,932 Reduced 87.4%
42,668 $1.74 Million
Q2 2023

Aug 14, 2023

BUY
$30.28 - $38.74 $8.9 Million - $11.4 Million
293,780 Added 655.47%
338,600 $12.2 Million
Q1 2023

May 15, 2023

BUY
$32.86 - $55.7 $54,219 - $91,905
1,650 Added 3.82%
44,820 $1.71 Million
Q4 2022

Feb 13, 2023

BUY
$40.06 - $59.44 $24,036 - $35,664
600 Added 1.41%
43,170 $2.46 Million
Q2 2022

Aug 12, 2022

SELL
$37.35 - $48.3 $133,115 - $172,141
-3,564 Reduced 7.73%
42,570 $1.87 Million
Q4 2021

Feb 11, 2022

SELL
$31.82 - $40.75 $4.99 Million - $6.39 Million
-156,909 Reduced 77.28%
46,134 $1.86 Million
Q3 2021

Nov 12, 2021

BUY
$38.47 - $46.42 $1.91 Million - $2.31 Million
49,732 Added 32.44%
203,043 $8.26 Million
Q1 2021

May 12, 2021

BUY
$39.51 - $51.45 $434,847 - $566,258
11,006 Added 7.73%
153,311 $6.39 Million
Q4 2020

Feb 12, 2021

BUY
$25.81 - $43.62 $2.32 Million - $3.91 Million
89,700 Added 170.52%
142,305 $6.08 Million
Q3 2020

Nov 12, 2020

BUY
$25.74 - $29.63 $1.12 Million - $1.29 Million
43,682 Added 489.54%
52,605 $1.38 Million
Q1 2020

May 11, 2020

SELL
$13.9 - $21.83 $124,043 - $194,810
-8,924 Reduced 50.0%
8,923 $161,000
Q4 2019

Feb 14, 2020

BUY
$14.93 - $19.53 $266,455 - $348,551
17,847 New
17,847 $316,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.